Exelon Panel To Debate Parkinson’s-Related Dementia As Distinct Condition
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis’ sNDA for the Alzheimer’s therapy is the first application for a Parkinson’s-related dementia indication.
You may also be interested in...
Exelon sNDA For Parkinson’s-Related Dementia Requires Just One Trial, Committee Says
FDA’s Peripheral & Central Nervous Systems Drugs Advisory Committee agrees that dementia associated with Parkinson’s disease qualifies as distinct from Alzheimer’s-type dementia.
Exelon sNDA For Parkinson’s-Related Dementia Requires Just One Trial, Committee Says
FDA’s Peripheral & Central Nervous Systems Drugs Advisory Committee agrees that dementia associated with Parkinson’s disease qualifies as distinct from Alzheimer’s-type dementia.
Exelon Dementia Indication May Revive Flagging Sales, Novartis Says
Sales of Novartis' Alzheimer's disease therapy Exelon (rivastigmine tartrate) have taken a hit in the U.S. due to increased competition, the company said